Biofrontera
BFRI
9 hedge funds and large institutions have $1.43M invested in Biofrontera in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 3 closing their positions.
36% more capital invested
Capital invested by funds: $1.05M → $1.43M (+$377K)
3.61% less ownership
Funds ownership: 22.97% → 19.36% (-3.6%)
25% less funds holding
Funds holding: 12 → 9 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
-$80.1K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$11.7K |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$10K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7.92K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$504 |
BFRI Hedge Fund Activity: Q3 2024 in Review
9 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Biofrontera (BFRI) for Q3 2024, worth a combined $1.43M — up 36% from $1.05M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BFRI and 0 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 0 added.
The largest seller was Scotia Capital, cutting an estimated $80.1K.
- 9 institutional investors held Biofrontera (BFRI) as of Q3 2024, down from 12 in Q2 2024.
- Funds reported $1.43M of Biofrontera stock for Q3 2024, up 36% quarter-over-quarter.
- 0 funds opened new Biofrontera positions in Q3 2024 and 3 closed out, a net change of -3 holders.
- The largest Biofrontera seller in Q3 2024 was Scotia Capital, an estimated $80.1K sold.
Based on aggregated 13F filings for Q3 2024.